Compass Pathways’ COMP360 Study: A New Hope for Treatment-resistant Depression?

Compass Pathways Plc ((CMPS)) announced an update on their ongoing clinical study.

Compass Pathways Plc is conducting a Phase III study titled A Phase III, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With Treatment-resistant Depression. The study aims to evaluate the efficacy, safety, and tolerability of COMP360, a psilocybin-based treatment, in individuals with treatment-resistant depression (TRD). This research is significant as it explores new therapeutic options for a condition with limited effective treatments.

The intervention being tested is COMP360, a psilocybin drug administered in doses of 25 mg, 10 mg, and 1 mg. The purpose of this intervention is to improve symptoms of depression in participants with TRD, with the support of psychological care.

The study design is interventional, randomized, and employs a parallel model with quadruple masking (participant, care provider, investigator, and outcomes assessor). The primary purpose is treatment, focusing on the therapeutic impact of COMP360 in TRD patients.

The study began on February 14, 2023, and is currently recruiting participants. The primary completion and estimated study completion dates are not specified, but the last update was submitted on August 1, 2025. These dates are crucial for tracking the study’s progress and anticipating results.

The update on this study could influence Compass Pathways’ stock performance and investor sentiment, as successful results may position the company as a leader in innovative depression treatments. This development is particularly relevant in the context of a growing interest in psychedelic therapies within the pharmaceutical industry.

The study is ongoing, and further details can be found on the ClinicalTrials portal.